Interstitial Lung Disease Ild clinical trials

Explore recruiting interstitial lung disease ild clinical trials.

Recruiting interstitial lung disease ild studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Interstitial Lung Disease Ild trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis

Hungary, Romania, Poland, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD).

Belgium, Netherlands, Germany, France, Greece, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Basket study for oligo-metastatic breast cancer - ANISE

Netherlands, France, Italy, Spain, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

Belgium, Italy, Spain, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)

Spain, Italy, Poland, France, Latvia, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

Netherlands, Czechia, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Interstitial Lung Disease Ild trials by city

Interstitial Lung Disease Ild in Toronto Interstitial Lung Disease Ild in Vancouver Interstitial Lung Disease Ild in Montreal Interstitial Lung Disease Ild in Calgary Interstitial Lung Disease Ild in Edmonton Interstitial Lung Disease Ild in Ottawa Interstitial Lung Disease Ild in Winnipeg Interstitial Lung Disease Ild in Quebec City Interstitial Lung Disease Ild in Hamilton Interstitial Lung Disease Ild in Kitchener Interstitial Lung Disease Ild in London Interstitial Lung Disease Ild in Halifax Interstitial Lung Disease Ild in New York Interstitial Lung Disease Ild in Los Angeles Interstitial Lung Disease Ild in Chicago Interstitial Lung Disease Ild in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease